These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6248221)

  • 41. Pharmacokinetics of cefotaxime in normal human volunteers.
    Esmieu F; Guibert J; Rosenkilde HC; Ho I; Le Go A
    J Antimicrob Chemother; 1980 Sep; 6 Suppl A():83-92. PubMed ID: 6252184
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparative pharmacokinetics of four new cephalosporins: moxalactam, cefotaxime, cefoperazone and ceftazidime in neonates.
    Bégué P; Safran C; Quiniou F; Lasfargues G; Quinet B
    Dev Pharmacol Ther; 1984; 7 Suppl 1():105-8. PubMed ID: 6097425
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacokinetics of cephanone in healthy adult volunteers.
    Regamey C; Kirby WM
    Antimicrob Agents Chemother; 1973 Dec; 4(6):589-92. PubMed ID: 4793878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cefoperazone pharmacokinetics in preterm infants.
    Bosso JA; Chan GM; Matsen JM
    Antimicrob Agents Chemother; 1983 Mar; 23(3):413-5. PubMed ID: 6221693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic effect of SF-2103A, a novel carbapenem antibiotic, in combination with cefotaxime, cefoperazone and other cephalosporins.
    Yoshida T; Kazuno Y; Shomura T; Murata S; Inouye S; Ito T
    J Antibiot (Tokyo); 1986 Jul; 39(7):956-65. PubMed ID: 3531130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of passage, in the vitreous body, of cefotaxime and cefoperazone].
    Carlhant D; Bonissent JF; Guedes Y; Le Garrec J; Rakotoseheno JC; Colin J; Riche C
    Therapie; 1987; 42(3):267-71. PubMed ID: 3660321
    [No Abstract]   [Full Text] [Related]  

  • 47. Entry of four cephalosporins into the ovine lung.
    Cohen SH; Hoeprich PD; Demling R; Gunther R; Merry JM; Franti CE; Miner DJ
    J Infect Dis; 1984 Feb; 149(2):264-70. PubMed ID: 6321609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cefotaxime pharmacokinetics following a single intravenous dose to patients with varying renal function.
    Nielsen OS; Toothaker RD; Bundtzen RW; Craig WA; Welling PG; Madsen PO
    Infection; 1980; 8 Suppl 3():S 305-9. PubMed ID: 6250981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Analysis of multiple cephalosporins in blood and urine by HPLC].
    Li M; Liao LC; Yan YY; Yang L; Liu XM; Dai J; Ma XN; Sheng X; Huang H; Su G
    Fa Yi Xue Za Zhi; 2009 Dec; 25(6):437-9. PubMed ID: 20225621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of cefotaxime, moxalactam, and cefoperazone in the early puerperium.
    Charles D; Larsen B
    Antimicrob Agents Chemother; 1986 May; 29(5):873-6. PubMed ID: 3729345
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)].
    Adam D; Pätzold J
    Infection; 1977; 5(4):228-31. PubMed ID: 598929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis.
    Boscia JA; Korzeniowski OM; Snepar R; Kobasa WD; Levison ME; Kaye D
    Antimicrob Agents Chemother; 1983 Mar; 23(3):385-9. PubMed ID: 6221691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cefoperazone concentrations in human aqueous humor after intravenous administration.
    Axelrod JL; Kochman RS
    Am J Ophthalmol; 1982 Jul; 94(1):103-5. PubMed ID: 6211988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole.
    Welage LS; Borin MT; Wilton JH; Hejmanowski LG; Wels PB; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2369-74. PubMed ID: 2088192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. III. Investigations of the mechanism of renal elimination.
    Ungethüm W; Pabst J; Dingeldein E; Leopold G
    Arzneimittelforschung; 1979; 29(2a):443-8. PubMed ID: 582723
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparison of cefoperazone and cefoxitin concentrations in serum and pelvic tissue of abdominal hysterectomy patients.
    Bawdon RE; Hemsell DL; Guss SP
    Antimicrob Agents Chemother; 1982 Dec; 22(6):999-1003. PubMed ID: 6218781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Dosage of Cefoperazone in Normal and Restricted Renal Function (author's transl].
    Piper C; Koeppe P; Höffler D
    MMW Munch Med Wochenschr; 1982 Mar; 124(10):244-8. PubMed ID: 6211612
    [No Abstract]   [Full Text] [Related]  

  • 58. [Determination of cefoperazone levels of the serum, bile and the gallbladder wall].
    Moorthi K; Gottschalk G
    Med Welt; 1983 Mar; 34(11):345-6. PubMed ID: 6221174
    [No Abstract]   [Full Text] [Related]  

  • 59. The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone--a novel galactose single-point method as a measure of residual liver function.
    Hu OY; Tang HS; Chang CL
    Biopharm Drug Dispos; 1994 Oct; 15(7):563-76. PubMed ID: 7849232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pharmacokinetic study of cefoperazone.
    Fujita K; Fujita HM
    Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):395-7. PubMed ID: 4044071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.